List view / Grid view
16 September 2013 | By Cancer Research Technology Ltd.
Cancer Research Technology and Teva Pharmaceutical have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells...
12 September 2013 | By Sanofi
Sanofi announced its decision to withdraw the lixisenatide New Drug Application (NDA) in the U.S...
12 September 2013 | By Bristol-Myers Squibb Company
Results from the Phase 3 randomized, double-blind clinical trial (Study 043)...
11 September 2013 | By Three Thinking Co.
Regulatory compliance specialist GXPi has announced the appointment of Richard Winning...
11 September 2013 | By AstraZeneca
AstraZeneca and Merck & Co Inc, announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK-1775)...
11 September 2013 | By Gilead Sciences
Gilead Sciences, Inc. has submitted a NDA to the U.S. FDA for approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of iNHL...
11 September 2013 | By Amgen
Study links RAS mutations to Vectibix clinical response in patients with metastatic colorectal cancer...
10 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the completion of patient enrolment for a Phase IIa clinical trial...
10 September 2013 | By GlaxoSmithKline
GSK and Theravance, Inc. announced that the PADAC to the US FDA voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol...
9 September 2013 | By Catalent Pharma Solutions
Catalent Pharma Solutions has named David Heyens in the new role of President of Catalent Asia Pacific...
9 September 2013 | By Merck
Merck announced that the NDA for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. FDA...
9 September 2013 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. announced that the companies have entered into a broad, multi-year collaboration...
9 September 2013 | By Boehringer Ingelheim
Data from two 48 week Phase III studies involving more than 3,000 patients...
9 September 2013 | By
In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy, the addition of tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation over 24 hours.1
9 September 2013 | By Boehringer Ingelheim
TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted...
